Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,382.00up ₹83.30 (3.62%)BSE ₹2,388.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹2,298.70.
2 Nov: open ₹2,306.00, high ₹2,400.10, low ₹2,306.00
52-week range of traded prices to 2 Nov 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹67,226 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.39
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.40
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 15,49,67347.5% delivered
Glenmark Pharmaceuticals share news and announcements
1,381 announcements, routine notices left out, newest first. Page 22 of 28.
Jul 2011
15 Jul · Board meeting
To consider and approve the Un-Audited Financial Results for the First Quarter ended June 30, 2011.12 Jul · Updates
The, "GBR 500 deal signed by Glenmark in May'2011 has received the second and final upfront payment of USD 25 million. With this payment, Glenmark has now received the entire upfront payment of USD 50 million from Sanofi pertaining to the GBR - 500 deal".
Jun 2011
27 Jun · Updates
Vide its letter dated June 27, 2011 that the GBR 500 deal signed by Glenmark in May'11 with Sanofi has received clearance from the Hart-Scott-Rodino Antitrust Improvements Act, USA. Following that clearance, the deal has now become effective and Glenmark has also received the first upfront payment of USD 25 million.17 Jun · Business
Board of Directors of the Company at its Operations Committee meeting held on June 17, 2011 allotted 7,900 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
May 2011
10 May · Management
Board of Directors of the Company at their meeting held on May 10, 2011 has announced the following changes to the Board effective from May 10, 2011: (1) Mr. Gracias Saldanha, Chairman has stepped down as the Chairman of the Board of Directors and has been re-designated as Founder & Chairman Emeritus; (2) Mr. Glenn Saldanha has been appointed as the Chairman of the Board in addition to his responsibilities as MD of the Company; (3) Mr. A. S. Mohanty ceases to be a director of the Company.10 May · Results
10 May · Results
Consolidated Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 294907 lacs for year ending on 31-MAR-2011 against Rs. 248484.55 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 45783.3 lacs for the year ending on 31-MAR-2011 against Rs. 33103.16 lacs for the year ending on 31-MAR-2010.10 May · Results
Standalone Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 115355.1 lacs for year ending on 31-MAR-2011 against Rs. 102191.05 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 21217.8 lacs for the year ending on 31-MAR-2011 against Rs. 12846.32 lacs for the year ending on 31-MAR-2010.10 May · Business
Board of Directors of the Company at its meeting held on May 10, 2011 allotted 4,650 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.10 May · Dividend
Board of Directors of the Company at its meeting held on May 10, 2011, has Recommend Dividend @ 40% i.e. Re.0.40 per share (face value Re.1/-) on the Equity Share Capital of the Company for the financial year 2010-2011 subject to the approval of the Shareholders at the ensuing Annual General Meeting.4 May · Business
Board of Directors of the Company at its Operations Committee Meeting held on May 04, 2011 allotted 47,150 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.2 May · Board meeting
(1) To consider and approve the Company's Audited Financial Statements for the Year ended March 31, 2011; (2) To consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2011.
Apr 2011
1 Apr · Disclosure
Compensation Commitee of the Company at its meeting held on March 30, 2011 has cancelled 408500 stock options pursuant to ESOS 2003, owing to employees leaving the services of the Company. Futher the Compensation Committee has issued 116000 stock options to permanent employees pursuant to ESOS 2003. Each option shall be convertible into one equity share of Re. 1/- each in one or more tranches.
Mar 2011
18 Mar · Business
Board of Directors of the Company at its Operations Committee Meeting held on March 18, 2011 allotted 10,350 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Feb 2011
16 Feb · Business
Board of Directors of the Company at its Operations Committee Meeting held on February 15, 2011 allotted 55,100 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.1 Feb · Results
Consolidated Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 75081.55 lacs for quarter ending on 31-DEC-2010 against Rs. 64168.46 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 10955.62 lacs for the quarter ending on 31-DEC-2010 against Rs. 9407.36 lacs for the quarter ending on 31-DEC-2009.1 Feb · Results
Standalone Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 31838.65 lacs for quarter ending on 31-DEC-2010 against Rs. 27691.66 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 5794.76 lacs for the quarter ending on 31-DEC-2010 against Rs. 3748.51 lacs for the quarter ending on 31-DEC-2009.
Jan 2011
24 Jan · Board meeting
To consider the Un-Audited Financial Results for the Third Quarter ended December 31, 2010.24 Jan · Business
Board of Directors of the Company, at its Operations Committee Meeting held on January 21, 2011 allotted 37,900 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Dec 2010
20 Dec · Business
Board of Directors of the Company, at its Operations Committee Meeting held on December 20, 2010 allotted 24,500 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Nov 2010
19 Nov · Business
Board of Directors of the Company, at its Operations Committee Meeting held on November 19, 2010 allotted 63,200 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Oct 2010
27 Oct · Business
Board of Directors of the Company, at its Board Meeting held on October 27, 2010 allotted 37,350 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.27 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 29316.7 lacs for quarter ending on 30-SEP-2010 against Rs. 23583.48 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 2754.29 lacs for the quarter ending on 30-SEP-2010 against Rs. 5750.18 lacs for the quarter ending on 30-SEP-2009.